Methods of treating inflammation using soluble IL-17RA/RC fusion proteins
    10.
    发明授权
    Methods of treating inflammation using soluble IL-17RA/RC fusion proteins 有权
    使用可溶性IL-17RA / RC融合蛋白治疗炎症的方法

    公开(公告)号:US08242072B2

    公开(公告)日:2012-08-14

    申请号:US13293384

    申请日:2011-11-10

    IPC分类号: A61K38/00

    摘要: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

    摘要翻译: 公开了IL-17A和IL-17F的拮抗剂。 拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白,包括包含IL-17RC和IL-17RA(“IL-17RC / IL-17RA”)部分的杂合可溶性受体。 这种拮抗剂用于阻断,抑制,降低,拮抗或中和IL-17F,IL-17A或IL-17A和IL-17F两者的活性。 还公开了使用这种拮抗剂治疗疾病,特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。